B-cell malignancy targets

The term B-cell malignancy targets refers to a broad category of molecular structures, including surface antigens and intracellular signaling proteins, that are exploited for the treatment of B-cell cancers such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, and multiple myeloma. Common therapeutic targets within this group include surface markers like CD19, CD20, and CD22, which are targeted by monoclonal antibodies and CAR-T cell therapies, as well as intracellular proteins like Bruton's tyrosine kinase (BTK) and B-cell lymphoma 2 (BCL-2), which are targeted by small molecule inhibitors. These targets play critical roles in B-cell development, survival, and proliferation; their dysregulation often leads to uncontrolled malignant growth. Because this entry represents a heterogeneous group of proteins rather than a single molecular entity, it is classified as an incorrect target name for specific biochemical annotation. Therapeutic intervention against these targets has revolutionized the treatment landscape for hematologic malignancies but often requires monitoring for side effects such as immune suppression and cytokine release syndrome.

Other names

B-cell lymphoma targetsB-cell leukemia targetsB-cell surface antigens

Various mechanisms including monoclonal antibody-mediated cytotoxicity, kinase inhibition, and induction of apoptosis.